Treatment of necrobiosis lipoidica with secukinumab (Cosentyx): a case series

Int J Dermatol. 2023 Sep;62(9):1198-1201. doi: 10.1111/ijd.16780. Epub 2023 Jul 1.

Authors

Ruby S Gibson¹, Prerna Salian¹, Ashley Beckles¹, Robert Stavert², Steven Tahan^{3

4}, Alexa B Kimball^{1

3}, Martina L Porter^{1

3}

Affiliations

¹ Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
² Science 37, Durham, NC, USA.
³ Harvard Medical School, Boston, MA, USA.
⁴ Division of Anatomic Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

PMID: 37392065
DOI: 10.1111/ijd.16780

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Diabetes Mellitus, Type 1*
Humans
Necrobiosis Lipoidica* / complications
Necrobiosis Lipoidica* / drug therapy

Substances

secukinumab
Antibodies, Monoclonal, Humanized

Grants and funding

Novartis